SCHEMBL15081043

SCHEMBL15081043

COC(=O)[C@H](Cc1ccc(NC(=O)C(C)=O)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK5 Q9Y337 1/20 0.52
HDAC8 Q9BY41 1/20 0.48
CTSS P25774 6/20 0.47
CTSK P43235 5/20 0.47
ITGB3 P05106 2/20 0.47
ITGA2B P08514 2/20 0.47
ITGB1 P05556 1/20 0.47
ITGAV P06756 1/20 0.47
ITGB5 P18084 1/20 0.47
PTPN1 P18031 2/20 0.47
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
ACE P12821 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12029082 1.00 KLK5 (0.52) KLK5HDAC8CTSSCTSKITGB3
SCHEMBL27278646 0.90 KLK5 (0.54) KLK5HDAC8CTSSCTSKITGB3
SCHEMBL12028739 0.89 ITGB3 (0.57) HDAC8CTSSCTSKITGB3ITGA2B
SCHEMBL15081044 0.89 ITGB3 (0.57) HDAC8CTSSCTSKITGB3ITGA2B
SCHEMBL22427549 0.87 KLK5 (0.53) KLK5HDAC8CTSSCTSKITGB3
SCHEMBL27278632 0.87 KLK5 (0.53) KLK5HDAC8CTSSCTSKITGB3
SCHEMBL19234613 0.85 KLK5 (0.59) KLK5HDAC8CTSSCTSKITGB3
SCHEMBL20865337 0.85 KLK5 (0.53) KLK5HDAC8CTSSCTSKITGB3
SCHEMBL20865305 0.85 KLK5 (0.53) KLK5HDAC8CTSSCTSKITGB3
SCHEMBL6679774 0.85 ITGB3 (0.51) KLK5HDAC8CTSSCTSKITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637441-B2 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides AMBRX, INC. (US) 2017-05-02 US disclosed
US-20150094457-A1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES AMBRX, INC. (US) 2015-04-02 US disclosed
US-8859802-B2 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides AMBRX, INC. (US) 2014-10-14 US disclosed
US-8846876-B2 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides Abrx, Inc. (US) 2014-09-30 US disclosed
US-8791231-B2 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides AMBRX, INC. (US) 2014-07-29 US disclosed
US-8476411-B2 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides AMBRX, INC. (US) 2013-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150094457-A1 COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES PTMS, DAO, DNPEP KLK5 3550/4885HDAC8 3647/4885CTSS 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.